Pasithea Therapeutics Corp. (KTTA) Posters https://ir.pasithea.com/company-information/posters/rss en-us https://d1io3yog0oux5.cloudfront.net/pasithea/files/theme/images/logo-sm.png Pasithea Therapeutics Corp. Logo Equisolve Investor Relations Suite <![CDATA[2025 NF1 Conference Poster: PHASE 1 TRIAL OF NEXT GENERATION MEK1/2 INHIBITOR PAS-004 IN ADULTS WITH INOPERABLE PLEXIFORM NEUROFIBROMAS]]> https://d1io3yog0oux5.cloudfront.net/_05d18125980f68b10dda47227ddfe7d3/pasithea/db/1979/17745/pdf/2025+NF1+CTF+Poster+%281%29.pdf Thu, 21 Aug 25 00:00:00 -0400 https://d1io3yog0oux5.cloudfront.net/_05d18125980f68b10dda47227ddfe7d3/pasithea/db/1979/17745/pdf/2025+NF1+CTF+Poster+%281%29.pdf <![CDATA[ASCO 2025 Poster Presentation: Phase I dose-escalation study of the safety and pharmacokinetics of PAS-004, a macrocyclic MEK inhibitor, for the treatment of patients with MAPK pathway–driven advanced solid tumors]]> https://d1io3yog0oux5.cloudfront.net/_05d18125980f68b10dda47227ddfe7d3/pasithea/db/1979/17743/pdf/Poster_06_2025_V3_%281%29.pdf Mon, 02 Jun 25 00:00:00 -0400 https://d1io3yog0oux5.cloudfront.net/_05d18125980f68b10dda47227ddfe7d3/pasithea/db/1979/17743/pdf/Poster_06_2025_V3_%281%29.pdf <![CDATA[ASCO 2024 Poster Presentation: PAS-004: A novel macrocyclic MEK inhibitor inhibits cancer cell growth in vitro and tumor growth in mouse xenograft studies]]> https://d1io3yog0oux5.cloudfront.net/_05d18125980f68b10dda47227ddfe7d3/pasithea/db/1979/17742/pdf/cartaz_ASCO_V5.pdf Mon, 03 Jun 24 00:00:00 -0400 https://d1io3yog0oux5.cloudfront.net/_05d18125980f68b10dda47227ddfe7d3/pasithea/db/1979/17742/pdf/cartaz_ASCO_V5.pdf